Education + Advocacy = Change

Click a topic below for an index of articles:

New-Material

Home

Alternative-Treatments

Financial or Socio-Economic Issues

Forum

Health Insurance

Hepatitis

HIV/AIDS

Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

 

If you would like to submit an article to this website, email us at info@heart-intl.net for a review of this paper

any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”

Herbal relief for hepatitis sufferers?
Berkeley researchers, reviewing clinical trials, find extracts from plants, roots, even toad skins potentially effective against this chronic disease

http://www.berkeley.edu/

By Sarah Yang, Public Affairs

02 October 2002 | Chinese herbal treatments, combined with standard therapy, may be more effective than standard therapy alone for treatment of chronic hepatitis B, according to an analysis of randomized, controlled trials led by Berkeley researchers.

Researchers analyzed 27 clinical trials in which chronic hepatitis B patients using Chinese herbal medicine alone, or in combination with the protein interferon alfa (the standard treatment for the infection), were compared with a control group of patients who were taking only interferon alfa. The meta-analysis, published this week in the American Journal of Public Health, found that the most encouraging results came from patients who used a combination of Chinese herbal treatments with interferon alfa.

“The results are encouraging enough that, if I had chronic hepatitis B and had previously failed interferon alfa treatment, I would talk to my doctor about combining interferon alfa with Chinese herbal medicine,” says Michael McCul-loch, a doctoral student in epidemiology at UC Berkeley’s School of Public Health and lead author of the study.

  

According to the World Health Organization, 2 billion people worldwide are infected with hepatitis B, 350 million of whom have the chronic form of the disease. About three-fourths of those with chronic hepatitis B, which increases the risk for primary liver cancer, live in Asia. Primary liver cancer is the fourth-leading cause of cancer death worldwide.

“There is a wealth of data about hepatitis B from researchers in Asia because the disease is endemic in that part of the world, but accessing that information has been — and still is — difficult because few of those studies are published in English-language journals,” says McCulloch, who is also a research fellow at the Chinese Academy of Sciences in Beijing.

McCulloch, a licensed acu-puncturist who earned his bachelor’s degree in Chinese studies at Berkeley, searched through six databases of medical literature, including clinical-trials data published in Chinese-language journals.

The ingredients in the herbal treatments included mixtures of plant and root extracts, and they varied from study to study. Two of the 27 studies specifically looked at bufotoxin, an extract from the skin of the toad Bufo gargarizans. Another two studied kurorinone, an extract from the root of the plant Sophorae flavescentis.

The authors included only trials in which patients using Chinese herbal medicine either alone or with interferon alfa were compared with a control group using only interferon alfa at least three times per week. The studies must also have included data on at least one of three markers of infection: levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA. All three measures indicate an active infection.

Overall, Chinese herbal medicine combined with interferon alfa was 1.5 to 2 times as effective as interferon alfa alone in reducing the hepatitis B viral load to undetectable levels for all three measures of infection. In particular, bufotoxin combined with interferon alfa was significantly more effective than interferon alfa alone in measures of HBeAg and HBV DNA, but not for measures of the surface antigen. Kurorinone was nearly as effective as interferon alfa in the two studies that tested it.

  

For measures of the surface antigen, patients receiving herbal treatment alone performed twice as well as those receiving only interferon alfa. The results did not differ significantly between the two groups for measures of HBeAg or HBV DNA.

“Bufotoxin and kurorinone have been singled out as having the best potential for being investigated for drugs,” says McCulloch, who is also a research fellow at the Chinese Academy of Sciences in Beijing. “However, it may be that the key to the way these herbal therapies work is by acting together as a group. That’s one of the great challenges in studying herbal treatments, yet it is one of the most fascinating aspects of Chinese medicines. These particular mixtures are a distillation of centuries of clinical use.”

The investigators also showed that the quality of the studies left much room for improvement. Many of the studies had incomplete information on how patients were randomized, and “blinding” of patients and doctors to the type of treatment administered did not occur in most of the studies.

“We cannot make firm conclusions about the use of Chinese herbal medicines based upon the results from these clinical trials,” says Dr. Jack Colford, associate professor of epidemiology at UC Berkeley’s School of Public Health and senior researcher for the study. “But the findings revealed by this analysis certainly justify additional investigation of these herbal therapies in more rigorous trials.”